We are excited to partner with the Malaria Consortium southsudan to conduct the Seasonal Malaria Chemoprevention Project End-of-round evaluation. Malaria Consortium is one of the world’s leading non-profit organisations dedicated to comprehensively controlling malaria and other communicable diseases in Africa and South East Asia.
See more about the consortium here: https://lnkd.in/dxpsKHEn
According to World Health Organization estimates, around 40% of the world’s population lives in malaria areas. Children under 5 and pregnant women are the most vulnerable populations in areas with stable transmission. The WHO African Region bears a disproportionate share of the global malaria burden, accounting for 95% of malaria cases and 96% of malaria deaths (WHO, 2023).
Seasonal malaria chemoprevention (SMC) is a highly effective, community-based intervention to prevent malaria infections caused by Plasmodium falciparum in areas where the burden of malaria is high and malaria transmission is seasonal. It involves the intermittent administration of an antimalarial to children aged 3–59 months during the peak malaria season (WHO, 2021). The objective is to maintain therapeutic antimalarial drug concentrations in the blood throughout this period of greatest risk. The WHO recommends annual SMC rounds comprising of monthly cycles beginning at the start of the transmission season. Each cycle involves the administration of full courses of sulfadoxine-pyrimethamine + amodiaquine (SPAQ) to eligible children.
We are proud to be supporting the consortium to enhance the National Malaria Control Program (NMCP) through high-quality research.
You can find more of our projects here: https://www.devcomglobal.com/projects/